Biliary effects of liraglutide and sitagliptin, a 12‐week randomized placebo‐controlled trial in type 2 diabetes patients

@inproceedings{Smits2016BiliaryEO,
  title={Biliary effects of liraglutide and sitagliptin, a 12‐week randomized placebo‐controlled trial in type 2 diabetes patients},
  author={Mark M Smits and Lennart Tonneijck and Marcel H. A. Muskiet and Trynke Hoekstra and Mark Kramer and Michaela Diamant and Max Nieuwdorp and Albert K. Groen and Djuna L. Cahen and Dani{\"e}l H van Raalte},
  booktitle={Diabetes, obesity & metabolism},
  year={2016}
}
AIMS Treatment with glucagon-like peptide (GLP)-1 receptor agonists or dipeptidyl peptidase (DPP)-4 inhibitors might increase gallstone formation; however, the mechanisms involved are unknown. We aimed to assess the effects of these drugs on gallbladder volume and bile acid profile. MATERIALS AND METHODS A total of 57 type 2 diabetes patients (mean ± SD age, 62.8 ± 6.9 years; BMI, 31.8 ± 4.1 kg/m2 ; HbA1c, 7.3% ± 0.6%), treated with metformin and/or sulfonylureas, were included in this 12… CONTINUE READING
BETA

References

Publications referenced by this paper.
SHOWING 1-10 OF 31 REFERENCES

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.

  • The New England journal of medicine
  • 2016
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…